347 related articles for article (PubMed ID: 20086018)
1. Neurofilament light as a prognostic marker in multiple sclerosis.
Salzer J; Svenningsson A; Sundström P
Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
[TBL] [Abstract][Full Text] [Related]
2. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
[TBL] [Abstract][Full Text] [Related]
3. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
5. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'.
Giovannoni G
Mult Scler; 2010 Mar; 16(3):285-6. PubMed ID: 20203146
[No Abstract] [Full Text] [Related]
8. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
9. [Neurofilament protein light in multiple sclerosis].
Zhang Y; Li X; Qiao J
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
[TBL] [Abstract][Full Text] [Related]
10. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
[TBL] [Abstract][Full Text] [Related]
12. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
[TBL] [Abstract][Full Text] [Related]
14. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.
Thangarajh M; Gomez-Rial J; Hedström AK; Hillert J; Alvarez-Cermeño JC; Masterman T; Villar LM
Mult Scler; 2008 Nov; 14(9):1208-13. PubMed ID: 18755821
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
16. The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
Calabrese M; Federle L; Bernardi V; Rinaldi F; Favaretto A; Varagnolo MC; Perini P; Plebani M; Gallo P
Mult Scler; 2012 Feb; 18(2):174-80. PubMed ID: 21868488
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.
Malmeström C; Andersson BA; Haghighi S; Lycke J
J Neuroimmunol; 2006 Jun; 175(1-2):176-82. PubMed ID: 16626811
[TBL] [Abstract][Full Text] [Related]
19. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
20. Neurofilaments as biomarkers in multiple sclerosis.
Teunissen CE; Khalil M
Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
